- Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)Keith W Crawford
Department of Clinical Pharmacology, Johns Hopkins University, Baltimore, MD 21287, USA
J Acquir Immune Defic Syndr 53:598-605. 2010..This substudy of AIDS Clinical Trials Group (ACTG) Protocol 5211 explored the relationship between antiretroviral effect and plasma concentrations of vicriviroc, an investigational CCR5 antagonist for HIV infection...
- Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavirKeith W Crawford
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 26:635-43. 2010..Age-related changes in the pharmacokinetics of antiretroviral drugs may be of increasing importance as the HIV-infected population ages and as older individuals comprise an increasing proportion of new diagnoses...
- Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statementKeith W Crawford
Johns Hopkins University, School of Medicine, Division of Clinical Pharmacology, Baltimore, MD, USA
Lancet Infect Dis 12:550-60. 2012..Optimising pharmacoenhancement and extending shelf life are additional strategies. The conference highlighted a range of interventions; optimum cost savings could be achieved through combining approaches...